Division of Infectious Diseases, University of Colorado, 12700 E. 19th Avenue, Mail Stop B168, Aurora, Denver, CO 80045, USA.
Int J Infect Dis. 2013 Jun;17(6):e374-8. doi: 10.1016/j.ijid.2012.11.030. Epub 2013 Jan 10.
Enterobacteriaceae bacteremia is a common complication in patients with neoplasm. The cancer itself, chemotherapy-induced immunosuppression, and other cancer-related procedures play a role as predisposing factors for this condition. However, despite the clear association between cancer and Enterobacteriaceae bacteremia, the distinctive clinical characteristics of patients with cancer presenting with Enterobacteriaceae bacteremia have not been well established.
The population studied was a prospective cohort of adult hospitalized patients with Enterobacteriaceae bacteremia in a tertiary care hospital. We compared the clinical variables and microbiological features between patients with an underlying neoplasm (n=203) and those without (n=259). STATA software was used for statistical association analysis.
In a bivariate analysis, older age, prior exposure to aminopenicillins, fewer days of symptoms, biliary source of bacteremia, greater severity of APACHE II score, lower white blood cell and platelet counts, and the presence of Klebsiella pneumoniae were more common in the neoplasm group. In a multivariable analysis, K. pneumoniae bacteremia (odds ratio (OR) 6.13, 95% confidence interval (CI) 1.65-22.71; p=0.007), APACHE II score (OR 1.18, 95% CI 1.05-1.34; p=0.007), and exposure to aminopenicillins (OR 28.84, 95% CI 1.94-429.3; p=0.015) were associated with neoplasm. K. pneumoniae bacteremia was more commonly present in patients with lung and gastrointestinal cancers.
We have confirmed the association of K. pneumoniae bacteremia with underlying neoplastic disease, especially with gastrointestinal malignancies, which may allow stratification for initial empiric antibiotic therapy in this subset of patients. Prior exposure to aminopenicillins in the neoplasm group might contribute to this finding.
肠杆菌科菌血症是肿瘤患者的常见并发症。癌症本身、化疗引起的免疫抑制以及其他与癌症相关的操作是导致这种情况的诱发因素。然而,尽管癌症与肠杆菌科菌血症之间存在明确的关联,但患有癌症并发生肠杆菌科菌血症的患者的独特临床特征尚未得到很好的确定。
本研究人群为一家三级保健医院住院的肠杆菌科菌血症成年患者的前瞻性队列。我们比较了有基础肿瘤(n=203)和无基础肿瘤(n=259)患者的临床变量和微生物学特征。STATA 软件用于统计关联分析。
在单变量分析中,年龄较大、先前暴露于氨芐西林、症状持续时间较短、胆道来源的菌血症、APACHE II 评分较高、白细胞和血小板计数较低以及存在肺炎克雷伯菌在肿瘤组中更为常见。在多变量分析中,肺炎克雷伯菌菌血症(比值比(OR)6.13,95%置信区间(CI)1.65-22.71;p=0.007)、APACHE II 评分(OR 1.18,95% CI 1.05-1.34;p=0.007)和暴露于氨芐西林(OR 28.84,95% CI 1.94-429.3;p=0.015)与肿瘤有关。肺炎克雷伯菌菌血症更常见于肺癌和胃肠道癌患者。
我们已经证实了肺炎克雷伯菌菌血症与基础肿瘤疾病的关联,特别是与胃肠道恶性肿瘤的关联,这可能允许对这部分患者进行初始经验性抗生素治疗的分层。肿瘤组中先前暴露于氨芐西林可能导致了这一发现。